---
title: "Weekly Recap | Alnylam Pharma -6.55%, consensus target above spot"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/298791370.md"
description: "Alnylam Pharma (ALNY) fell 6.55% this week to $248.68, closing well behind the S&P 500’s 0.8% decline and underperforming by about 5.75 percentage points. The week held no major catalysts. The stock rallied early, touching $272.08 intraday on Tuesday, 8 September, before slipping through the rest of the week. Thursday, 10 September, marked the week’s low around $246.01, with a modest recovery into Friday’s close. The weekly swing exceeded 10%, within a 60-day range of $197.81 to $380."
datetime: "2026-09-12T05:55:27.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/298791370.md)
  - [en](https://longbridge.com/en/news/298791370.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/298791370.md)
generator: "portal-rs"
---

# Weekly Recap | Alnylam Pharma -6.55%, consensus target above spot

## The Week

Alnylam Pharma (ALNY) fell 6.55% this week to $248.68, closing well behind the S&P 500’s 0.8% decline and underperforming by about 5.75 percentage points. The week held no major catalysts. The stock rallied early, touching $272.08 intraday on Tuesday, 8 September, before slipping through the rest of the week. Thursday, 10 September, marked the week’s low around $246.01, with a modest recovery into Friday’s close. The weekly swing exceeded 10%, within a 60-day range of $197.81 to $380. The 20-day and 60-day moving averages sit at $243.89 and $261.30 respectively.

## Analyst Ratings

Across 29 firms covering the stock, 22 rate it buy or overweight and 7 rate it hold, with no sell or underweight ratings. The consensus rating is buy, with a consensus target of $371.35, roughly 49.33% above the latest close. Targets range from $256 to $536, showing wide dispersion. Within a biotech peer group of 506 names, ALNY ranks 5th by analyst rating.

## The Week Ahead

US macro data dominates next week. Tuesday, 15 September brings the New York Fed manufacturing index, with consensus at 14.75 versus a prior 20.6. Wednesday, 16 September features retail sales and the NAHB housing market index. Consensus for retail sales excluding autos is 0.6, up from -0.3; the NAHB index is seen at 34, slightly below the prior 35. These releases will offer fresh signals on US consumption and manufacturing momentum.

*This article is generated by LongbridgeAI from market data, for information only and not investment advice.*

### Related Stocks

- [ALNY.US](https://longbridge.com/en/quote/ALNY.US.md)

## Related News & Research

- [Alnylam Highlights AMVUTTRA Momentum, Resets 2026 TTR Revenue Outlook](https://longbridge.com/en/news/299562227.md)
- [Alnylam Pharmaceuticals (ALNY) Gains Attention After Fresh RNAi Data, Is It 33% Undervalued?](https://longbridge.com/en/news/298836244.md)
- [Alnylam's Sell-Off Looks Ugly -- but Wall Street Still Sees a Much Brighter Picture](https://longbridge.com/en/news/299024235.md)
- [Alnylam’s Zilebesiran Targets Twice-Yearly Blood Pressure Control in ZENITH Trial](https://longbridge.com/en/news/299535881.md)
- [Micron Stock's (MU) AI Lead Is Expanding beyond HBM. I'm Bullish](https://longbridge.com/en/news/299626350.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**